Phase 4Terminated
NuvaRing Versus Marvelon in the Coordination of In Vitro Fertilization Cycles
Effect of Using the Nuvaring on the Level of Satisfaction, Stress on Users and on Coordinating In Vitro Fertilization (IVF) Cycles: Randomized Public Study
- Sponsor
- Clinique Ovo (Industry)
- Enrollment
- 7 enrolled
- Conditions
- Infertility
- Interventions
- Contraceptives, Oral; Contraceptive, Vaginal ring
- Ages
- adults
- Registry
- NCT01638767
Full record on ClinicalTrials.gov
From the registry
Presently, a long protocol in an In Vitro Fertilization (IVF) cycle, patients need to take Marvelon, a drug that inhibits the follicular development at the beginning of the cycle in order to better control and also plan the onset of the ovary stimulation with gonadotropin. Marvelon is taken daily as soon as menstruation starts for a period of 14 to 21 days. Ideally, it has to be taken at the same time everyday and not be forgotten. This may cause higher stress level for some users. Presently on the market, there is a ring-shaped contraceptive device inserted in the vagina at day 1 of the cycle called NuvaRing. The purpose of this device is similar to an oral contraceptive. However, the benefit of NuvaRing is that it can be left in place for a period of up to 35 days without any other manipulation and keep an adequate rate of hormone for contraception. Moreover, NuvaRing shows better hormone stability in the blood. Although the side effects and the benefits are comparable for the two treatments, some studies have shown that more patients would respect the treatment with NuvaRing and…
Primary outcomes
- The level of satisfaction in patients in relation to contraceptive medication
- The level of stress experienced by patients in relation to contraceptive medication
- Patient's adherence to the treatment
- The number of patients who had bleeding during their contraceptive treatment
History
Last registry update
Primary completion
Started
Registered